Substantial differences were found in terms of pricing. In the Czech Republic, the Ministry of Finance sets maximal prices for pharmaceuticals whereas in Sweden there is a process of price regulation combined with reimbursement decisions taken by the Pharmaceutical Benefits Board. Together with a system of state-owned pharmacies, this ensures that
drug prices in Sweden are fixed at the same level throughout the country. In the Czech Republic, prices may differ, since only maximal price levels are set. The private share of pharmaceutical expenditures is substantially lower in the Czech Republic, even though there is no maximal level for patient’s co-payment, as there is in Sweden. The research article states that both systems are designed to promote rational and cost-effective use of drugs; and are based on social solidarity.
Stiahnuť dokument